From Nasdaq: 2025-02-08 23:36:47

Regeneron Pharmaceuticals Inc. announced positive results from the Phase 3 QUASAR trial, testing EYLEA HD for macular edema due to retinal vein occlusion. Data supports a Biologics License Application submission to the FDA in Q1 2025. EYLEA HD showed non-inferior visual acuity gains compared to EYLEA. Results were consistent across different types of vein occlusions. 88% of patients sustained an 8-week dosing regimen. Safety profile was similar to EYLEA, with ocular TEAEs including increased ocular pressure. EYLEA HD is jointly developed by Regeneron and Bayer AG worldwide. Regeneron has exclusive rights in the U.S. Visit rttnews.com for more health news.



Read more at Nasdaq: Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment